Wasn't there something in the literature that mentioned that Pona could actually prevent the T315i mutation from actually gaining traction? Wasn't this one of the arguments that Cortes (or someone on his team) made in respect to using Pona as front-line therapy?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.